StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$251.41+0.62 (+0.25%)

Close on Nov 18, 2026Market cap $37.16BP/E 107.4Yield –

Biogen price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Biogen's price to book ratio was 2.1× on Apr 30, 2024, against 3.3× a year earlier. Over the last 5 years it ranged from 2.1× to 5.1×, with a median of 3.5×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Apr 30, 20242.1×−0.5
2023Dec 29, 20232.6×−0.6
2022Dec 30, 20223.2×−0.3
2021Dec 31, 20213.5×−0.3
2020Dec 31, 20203.8×−0.3
2019Dec 31, 20194.1×−0.5
2018Dec 31, 20184.6×−0.8
2017Dec 29, 20175.3×+0.2
2016Dec 30, 20165.1×−1.7
2015Dec 31, 20156.8×−0.9
2014Dec 31, 20147.7×−0.5
2013Dec 31, 20138.2×+2.8
2012Dec 31, 20125.4×+0.9
2011Dec 30, 20114.5×+0.7
2010Dec 31, 20103.8×+1.4
2009Dec 31, 20092.4×–

More Biogen figures

See a number that looks wrong?